Pallavy Reddy, MD
Endocrinology, Diabetes & Metabolism · Dublin, OHNPI 1740277664
Payments from drug & device makers
Across 749 payments — averaging $32.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$15K
- Novo Nordisk$2K
- Dexcom, Inc.$811
- Mannkind Corporation$735
- Lilly USA, LLC$495
- Amgen$460
- plus $5K from 41 others
What the payments were for
- Speaking & faculty fees$14,50060%
- Food & beverage$9,71840%
- Education$520%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$9,310
- t:slim X2 insulin pump$5,300
- DEXCOM G6 TRANSMITTER$330
- Ozempic$214
- Tresiba$111
- MYALEPT$110
- PRALUENT$107
How this compares
$24,288 in reported general payments places this provider in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 196 | $350,944 |
| MounjaroTirzepatide | 213 | $334,535 |
| ProliaDenosumab | 99 | $174,545 |
| TrulicityDulaglutide | 83 | $132,561 |
| JardianceEmpagliflozin | 111 | $121,574 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 76 | $115,497 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $113,098 |
| FarxigaDapagliflozin Propanediol | 88 | $96,114 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $72,489 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $64,554 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $45,389 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 41 | $41,819 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $36,883 |
| KerendiaFinerenone | 29 | $35,285 |
| TymlosAbaloparatide | 13 | $34,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $495 | $476,381318 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,646 | $388,409238 claims |
| AmgenProlia | $460 | $174,54599 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $407 | $166,964143 claims |
| AstraZenecaFarxiga | $292 | $96,11488 claims |
| MerckJanumet Xr, Januvia | $207 | $72,13872 claims |
| BayerKerendia | $37 | $35,28529 claims |
| Radius Health, Inc.Tymlos | $213 | $34,89013 claims |
| Johnson & JohnsonInvokana | $290 | $27,90924 claims |
| AbbVieSynthroid, Armour Thyroid | $257 | $26,808279 claims |
| IBSA Pharma Inc.Tirosint | $103 | $11,88734 claims |
| Amneal Pharmaceuticals LLCUnithroid | $315 | $11,152333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Dublin
- Jennifer RittenberryDublin$141K
- Elizabeth BuschurDublin$31K
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.